Jasper Therapeutics, Inc.
JSPRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeJasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The $23.6M market capitalization puts JSPR squarely in micro-cap range for its industry. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.
Market Cap
$23.6M
Beta
3.04
P/E (TTM)
—
P/E (Fwd)
-0.28
EPS (TTM)
$-0.93
EPS (Fwd)
$-2.56
ROE
-255.1%
ROA
-113.4%
Cash
$7.3M
Total Debt
$270,000
Free CF
-$40.0M
52W Change
-72.5%
Annual Financials
Cash vs Debt
Where JSPR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, JSPR finished 20.45% below its 150-day moving average ($0.88) and 35.78% below its 200-day moving average ($1.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JSPR overbought or oversold?
At the September 3, 2026 close, JSPR's RSI(14) was 28.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Jasper Therapeutics, Inc. holds $7.3M in cash against $270K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$40.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -255.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Jasper Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, JSPR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Jasper Therapeutics, Inc. and its sector.